<DOC>
	<DOCNO>NCT00658827</DOCNO>
	<brief_summary>The purpose study collection analysis information pertain pregnancy outcome woman expose infliximab pregnancy , relative background risk similar non-biologic exposed patient ; information pertain health status , first year follow delivery , infant bear woman follow prenatal exposure infliximab unexposed counterpart .</brief_summary>
	<brief_title>Analysis Birth Outcomes Swedish , Danish Finnish Women Exposed Remicade With Inflammatory Bowel Disease , Rheumatoid Arthritis , Psoriatic Arthritis , Ankylosing Spondylitis , Psoriasis</brief_title>
	<detailed_description>This registry analyze birth outcome data Medical Birth Registers approximately 370 woman become pregnant exposed infliximab diseases interest : Inflammatory Bowel Disease ( Crohn 's Disease [ CD ] Ulcerative Colitis [ UC ] ) , Rheumatoid Arthritis [ RA ] , Psoriatic Arthritis [ PsA ] , Ankylosing Spondylitis [ AS ] , Psoriasis ( Pso ) well woman disease expose infliximab . Demographics information relate diseases interest , past medical history , infliximab exposure pregnancy ( 3 month prior conception ) , use medication , pregnancy outcome information infant birth information collect Swedish national health registry ( a. Swedish Medical Birth Register [ SMBR ] b. Swedish Prescribed Drug Register c. Swedish Patient Register [ PAR ] ) , Danish national health registry ( a. Danish Medical Birth Register [ DMBR ] b. Danish Register Medicinal Product Statistics c. Danish National Patient Registry ) , Finnish national health registry ( a. Finnish Medical Birth Register [ FMBR ] b. Finnish Register Prescribed Medicine c. Finnish National Care Register Health Care Institutions [ HILMO ] d. Finnish Register Congenital Malformations ) study period . The health status infant bear woman follow 1 year birth . During 1-year follow-up period , information related hospitalization antibiotic use obtain . No study medication administer registry . Treatments prescribed physician basis usual clinical practice .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Study patient must meet following criterion : Women childbearing age birth outcomes record either Swedish Medical Birth Register ( SMBR ) , Finnish Medical Birth Register ( FMBR ) Danish Medical Birth Register ( DMBR ) confirm diagnosis Crohn 's disease , ulcerative colitis , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis , psoriasis document exposure infliximab pregnancy infant born woman Control patient must meet following criterion : Women childbearing age birth outcomes record either SMBR , FMBR DMBR confirm diagnosis Crohn 's disease , ulcerative colitis , rheumatoid arthritis , psoriatic arthritis , ankylose spondylitis psoriasis , exposure biologics pregnancy infant born woman Information woman document history disease interest whose birth outcome include SMBR , FMBR DMBR study period infant woman</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Inflammatory Bowel Disease</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>Ankylosing Spondylitis</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Pregnant woman expose infliximab</keyword>
</DOC>